Guardion Health Sciences Restores Compliance with Nasdaq Minimum Offer Price Rule

/ EIN News / – SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition and diagnostic company that develops of Supported Nutritional Supplements, Medical Foods and Medical Devices, announced that it was once again compliant with the minimum bid price requirement for continued listing on the Nasdaq capital market under the rule of entry 5550 (a) (2) (the “minimum bid price rule”). On March 15, 2021, Guardion received a letter from the legal counsel’s office of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that because the common shares of Guardion’s Company (the “Common Shares”) had an equal closing bid price or greater than $ 1.00. per share for at least ten (10) consecutive trading days, its common stock again complied with the Nasdaq minimum offer price rule.

On September 20, 2019, the Company received a notice from Nasdaq indicating that, based on the closing bid price of the common shares, the Company no longer met the minimum bid price rule. The Company had 180 calendar days, or until March 18, 2020, to re-comply with the minimum bid price rule. Subsequently, the Company was granted a second compliance period of 180 calendar days (of which the 180-day period was extended due to circumstances related to COVID-19), or until November 30, 2020, to to comply again with the rule of the minimum offer price.

The Company has not been able to re-comply with the minimum bid price rule by November 30, 2020. Therefore, on December 1, 2020, the Company received a letter from Nasdaq informing it that its Common shares would be subject to delisting from the Nasdaq unless the Company timely requests a hearing before a qualifying panel for listing on the Nasdaq (the “panel”). The Company requested the hearing in due course.

Following the hearing, on January 26, 2021, the Company received a written notification indicating that the Panel had granted the Company an extension to maintain registration until March 15, 2021. As stated above , the Nasdaq determined that the Company had complied with the Panel’s decision and had recovered compliance. As a result, the Nasdaq closed the compliance review.

About Guardion Health Sciences

Guardion Health Sciences, Inc. (NASDAQ: GHSI) is a clinical nutrition and diagnostic company. Guardion offers a range of scientifically supported and clinically supported nutrition, medical food and diagnostic products that help healthcare professionals, their patients and consumers achieve their health goals. Guardion’s business and development initiatives are supported by equally impressive scientific and medical advisory boards, led by senior business executives and physicians with many years of experience. This combination of expertise and scientific knowledge forms the foundation for Guardion’s growing position within the eye care industry and clinical nutrition market. Information and risk factors regarding Guardion and its business, including its ability to successfully develop and market its proprietary products and technologies, may be obtained from the documents filed by the Company with the United States Securities and Exchange Commission. (the “SEC”) at www.sec .gov.

Disclaimer Regarding Forward-Looking Statements

Except for historical information contained in this press release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. , as amended. Statements preceded, followed by or which otherwise include the words “believes”, “expects”, “anticipates”, “intends”, “projects”, “estimates”, “plans” and similar expressions or future or conditional verbs such as “” will “,” should “,” would “,” could “and” could “are generally forward-looking in nature and not historical facts, although not all forward-looking statements include what is precedes. These statements involve unknown risks and uncertainties which may have an individual or material impact on the matters discussed in this document for various reasons beyond the control of the Company, including, but not limited to the ability of the Company. Company to raise sufficient funding to implement its activities. plan, the integration of a new management team, the impact of the COVID-19 pandemic on the business, operations and economy of the Company in general, the ability of the Company to develop and market successfully its proprietary products and technologies; and the Company’s ability to maintain compliance with Nasdaq listing requirements. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set out in the Company’s filings with the SEC, which are available on the SEC’s website ( The Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Scott arnold
[email protected]

Contact person for media relations:
Jules Abraham
Director of Public Relations
[email protected]

Source link

Previous UW System Orders Audit in Bidding Process for UW-Madison Project | Higher Education
Next FIFA President promises 'bulletproof' bidding process for 2030 World Cup

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *